Asciminib, ASCIMINIB HYDROCHLORIDE clinical trials

A phase II, multicenter, open-label, single arm study to evaluate the safety and efficacy of asciminib in pediatric participants newly diagnosed or previously treated with Philadelphia positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) with or without known T315I mutation

This study is looking at a new medicine, asciminib, for children and young people with a specific type of blood cancer called Philadelphia positive Chronic Myeloid Leukaemia (CML). It aims to see how safe and effective it is in helping their leukaemia go into remission.